{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363388846291533696.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/j.1445-5994.2012.02886.x"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1445-5994.2012.02886.x"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1445-5994.2012.02886.x"}}],"dc:title":[{"@value":"Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Due to multiple beneficial effects, including control of disease activity, reduction in cardiovascular events and improved survival, hydroxychloroquine is now recommended long‐term for all patients with systemic lupus erythematosus. However, patients must be made aware of the possible risk of retinal toxicity and have eye examinations to monitor for this complication. As hydroxychloroquine becomes more widely used in systemic lupus erythematosus, physicians must also be aware of rare but serious adverse effects, including neuromyotoxicity and cardiotoxicity.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380285706277828993","@type":"Researcher","foaf:name":[{"@value":"C. Tang"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388846291533697","@type":"Researcher","foaf:name":[{"@value":"T. Godfrey"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388846291533699","@type":"Researcher","foaf:name":[{"@value":"R. Stawell"}]},{"@id":"https://cir.nii.ac.jp/crid/1383388846291533698","@type":"Researcher","foaf:name":[{"@value":"M. Nikpour"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"14440903"},{"@type":"EISSN","@value":"14455994"}],"prism:publicationName":[{"@value":"Internal Medicine Journal"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2012-09","prism:volume":"42","prism:number":"9","prism:startingPage":"968","prism:endingPage":"978"},"reviewed":"false","dc:rights":["http://doi.wiley.com/10.1002/tdm_license_1"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1445-5994.2012.02886.x"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1445-5994.2012.02886.x"}],"createdAt":"2012-07-25","modifiedAt":"2023-10-15","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285709229868416","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Disease flare patterns and predictors of systemic lupus erythematosus in a monocentric cohort of 423 Japanese patients during a long-term follow-up: The JUDE study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848659183383424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chloroquine attenuates TLR3/IFN-β signaling in cultured normal human mesangial cells: A possible protective effect against renal damage in lupus nephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390568772523843584","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Three Cases of Drug Discontinuation due to Adverse Events in Systemic Lupus Erythematosus Patients Administered Hydroxychloroquine"}]},{"@id":"https://cir.nii.ac.jp/crid/2051996266985195904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Chloroquine attenuates TLR3-mediated plasminogen activator inhibitor-1 expression in cultured human glomerular endothelial cells"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/j.1445-5994.2012.02886.x"},{"@type":"CROSSREF","@value":"10.1007/s10157-018-1659-y_references_DOI_EujZJ8dpv7nFJUPBmxtmFpEVHbw"},{"@type":"CROSSREF","@value":"10.1080/14397595.2016.1192745_references_DOI_EujZJ8dpv7nFJUPBmxtmFpEVHbw"},{"@type":"CROSSREF","@value":"10.5649/jjphcs.46.146_references_DOI_EujZJ8dpv7nFJUPBmxtmFpEVHbw"},{"@type":"CROSSREF","@value":"10.1080/14397595.2017.1289646_references_DOI_EujZJ8dpv7nFJUPBmxtmFpEVHbw"}]}